Last 12 months
Inside the activity.
0 purchase rows · 78 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 35 |
| Mar 2026 | 0 | 13 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 1,986 | $367.29 | $729,440.12 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 6 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,465,583 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F9 · price: Purchase prices range from $366.83 to $367.81 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 3,979 | $366.05 | $1,456,524.09 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 5 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,463,597 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F8 · price: Purchase prices range from $365.80 to $366.73 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 19,858 | $365.20 | $7,252,177.34 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 4 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,459,618 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F7 · price: Purchase prices range from $364.80 to $365.79 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 13,226 | $364.32 | $4,818,528.06 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 3 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,439,760 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F6 · price: Purchase prices range from $363.80 to $364.77 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 6,546 | $363.35 | $2,378,511.36 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 2 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,426,534 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F5 · price: Purchase prices range from $362.80 to $363.79 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:15 UTC |
Sanofi10% owner
|
PurchaseCommon Stock | 1,592 | $362.47 | $577,046.51 |
DisclosureSEC source: 0001140361-17-001832 · form4.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 23,419,988 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · shares: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). F1 · price: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3 · price: Purchase prices range from $361.76 to $362.71 per share, inclusive. F4 · ownership.nature: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:47 UTC |
Bassler Bonnie LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,438 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000007 · edgardoc.xml · derivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,438 Underlying: Common Stock · 2,438 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:48 UTC |
POON CHRISTINE ADirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000008 · edgardoc.xml · derivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:14 UTC |
BROWN MICHAEL SDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000005 · edgardoc.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:13 UTC |
GOLDSTEIN JOSEPH LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000004 · edgardoc.xml · derivative · entry 1 GOLDSTEIN JOSEPH L · CIK 0001225474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:13 UTC |
RYAN ARTHUR FDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000003 · edgardoc.xml · derivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:12 UTC |
SING GEORGE LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000002 · edgardoc.xml · derivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:12 UTC |
SING GEORGE LDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $19.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000002 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:12 UTC |
SING GEORGE LDirector
|
Exercise / conversionCommon Stock | 7,000 | $19.69 | $137,830.00 |
DisclosureSEC source: 0001237899-17-000002 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:10 UTC |
Zoghbi Huda YDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,438 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000001 · edgardoc.xml · derivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,438 Underlying: Common Stock · 2,438 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:05 UTC |
BAKER CHARLES ADirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000010 · edgardoc.xml · derivative · entry 1 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:03 UTC |
Tessier-Lavigne MarcDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000009 · edgardoc.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed May 26, 2017 20:04 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
GiftCommon Stock | 571 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000017 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 151,254 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC |
YANCOPOULOS GEORGEDirector · President & CSO
|
GiftCommon Stock | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 64,058 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC |
YANCOPOULOS GEORGEDirector · President & CSO
|
GiftCommon Stock | 536 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 64,594 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC |
YANCOPOULOS GEORGEDirector · President & CSO
|
GiftCommon Stock | 670 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 65,130 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC |
YANCOPOULOS GEORGEDirector · President & CSO
|
GiftCommon Stock | 1,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 65,800 Read SEC document |
| December 20, 2016 Filed Feb 11, 2017 01:31 UTC |
YANCOPOULOS GEORGEDirector · President & CSO
|
GiftCommon Stock | 1,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000014 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 66,871 Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:16 UTC |
Van Plew Daniel PEVP & General Mgr Industrial O
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000091 · edgardoc.xml · derivative · entry 1 Van Plew Daniel P · CIK 0001411984 · EVP & General Mgr Industrial O 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:09 UTC |
YANCOPOULOS GEORGEDirector · President Regeneron Laboratori
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 146,815 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · derivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,815 Underlying: Common Stock · 146,815 shares Expires 2026-12-16 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:18 UTC |
LAROSA JOSEPH JSVP General Counsel and Secret
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,565 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000093 · edgardoc.xml · derivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · SVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,565 Underlying: Common Stock · 24,565 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:17 UTC |
Aberman Michael SSVP Strategy Investor Relation
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,675 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000092 · edgardoc.xml · derivative · entry 1 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,675 Underlying: Common Stock · 21,675 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:16 UTC |
Terifay Robert JEVP Commercial
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000090 · edgardoc.xml · derivative · entry 1 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:15 UTC |
Powchik PeterSVP Clinical Development & Reg
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000089 · edgardoc.xml · derivative · entry 7 Powchik Peter · CIK 0001377247 · SVP Clinical Development & Reg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-12-16 F3 · derivative.exercise_date: The stock option award vests in full one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:14 UTC |
Landry Robert ESVP Finance & CFO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,565 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000088 · edgardoc.xml · derivative · entry 1 Landry Robert E · CIK 0001585160 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,565 Underlying: Common Stock · 24,565 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:07 UTC |
SCHLEIFER LEONARD SDirector · President & CEO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 146,815 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · derivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,815 Underlying: Common Stock · 146,815 shares Expires 2026-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:29 UTC |
VAGELOS P ROYDirector · Chairman of the Board
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 78,302 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000095 · edgardoc.xml · derivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,302 Underlying: Common Stock · 78,302 shares Expires 2026-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:28 UTC |
STAHL NEILEVP Research and Development
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 58,342 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000094 · edgardoc.xml · derivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,342 Underlying: Common Stock · 58,342 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 14, 2018 21:21 UTC |
YANCOPOULOS GEORGEDirector · President and CSO
|
GiftCommon Stock | 89,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 14 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 159,324 Read SEC document |
| December 16, 2016 Filed Dec 14, 2018 21:21 UTC |
YANCOPOULOS GEORGEDirector · President and CSO
|
GiftCommon Stock | 89,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073103 · a4.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:09 UTC |
YANCOPOULOS GEORGEDirector · President Regeneron Laboratori
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 195,079 | $0.00 Strike: $20.32 | $0.00 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · derivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,079 shares Expires 2016-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:09 UTC |
YANCOPOULOS GEORGEDirector · President Regeneron Laboratori
|
Tax withholdingCommon Stock | 95,223 | $380.09 | $36,193,310.07 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,348 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:09 UTC |
YANCOPOULOS GEORGEDirector · President Regeneron Laboratori
|
Tax withholdingCommon Stock | 10,429 | $380.09 | $3,963,958.61 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,571 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:09 UTC |
YANCOPOULOS GEORGEDirector · President Regeneron Laboratori
|
Exercise / conversionCommon Stock | 195,079 | $20.32 | $3,964,005.28 |
DisclosureSEC source: 0001237899-16-000087 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President Regeneron Laboratori 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 697,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:07 UTC |
SCHLEIFER LEONARD SDirector · President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $20.32 | $0.00 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · derivative · entry 5 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2016-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:07 UTC |
SCHLEIFER LEONARD SDirector · President & CEO
|
Tax withholdingCommon Stock | 122,032 | $380.09 | $46,383,142.88 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,409 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:07 UTC |
SCHLEIFER LEONARD SDirector · President & CEO
|
Tax withholdingCommon Stock | 13,365 | $380.09 | $5,079,902.85 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,441 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:07 UTC |
SCHLEIFER LEONARD SDirector · President & CEO
|
Exercise / conversionCommon Stock | 250,000 | $20.32 | $5,080,000.00 |
DisclosureSEC source: 0001237899-16-000086 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC |
BAKER CHARLES ADirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · derivative · entry 7 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 3,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC |
BAKER CHARLES ADirector
|
SaleCommon Stock | 200 | $394.33 | $78,866.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 6 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on December 12, 2016 at prices ranging from $394.24 to $ 394.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC |
BAKER CHARLES ADirector
|
SaleCommon Stock | 600 | $393.64 | $236,184.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 5 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on December 12, 2016 at prices ranging from $393.39 to $393.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC |
BAKER CHARLES ADirector
|
SaleCommon Stock | 400 | $392.41 | $156,964.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 4 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on December 12, 2016 at prices ranging from $392.00 to $392.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC |
BAKER CHARLES ADirector
|
SaleCommon Stock | 1,200 | $391.36 | $469,632.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 3 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 1,200 shares of Company stock on December 12, 2016 at prices ranging from $391.02 to $391.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC |
BAKER CHARLES ADirector
|
SaleCommon Stock | 600 | $390.67 | $234,402.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 2 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,400 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 600 shares of Company stock on December 12, 2016 at prices ranging from $390.26 to $390.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 12, 2016 at each separate price. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 22:41 UTC |
BAKER CHARLES ADirector
|
Exercise / conversionCommon Stock | 3,000 | $18.61 | $55,830.00 |
DisclosureSEC source: 0001237899-16-000085 · edgardoc.xml · nonDerivative · entry 1 BAKER CHARLES A · CIK 0001225470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.